54
Participants
Start Date
August 31, 2001
Primary Completion Date
March 31, 2005
Study Completion Date
April 30, 2009
Taxotere
Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
Cisplatin
Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
Irinotecan
Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Faulkner Hospital, Boston
Collaborators (1)
Massachusetts General Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Brigham and Women's Hospital
OTHER
Aventis Pharmaceuticals
INDUSTRY
Dana-Farber Cancer Institute
OTHER